This performance of the ONECUT2 methylation test was better than the one reported previously (sensitivity of 82% and specificity of 62% with a panel of VIM, RASSF1A, GDF15, and TMEFF2 methylation in UTUC group) (18). The gene discussed is VIM; the disease is renal pelvis/ureter urothelial carcinoma.